Baltimore biologics company Paragon Bioservices will open a new commercial manufacturing facility near BWI Thurgood Marshall Airport.
Paragon is a biologics contract development and manufacturing organization that has worked in gene therapy and next-generation vaccines. The company said increased client need for broad gene therapy manufacturing was a leading factor in the expansion.
The 150,000-foot facility is expected to add as many as 200 jobs. The the company expects to start using the space in the fourth quarter, including for Phase I and Phase II clinical trials.
Paragon expects the facility to be ready for commercial manufacturing within 18 to 24 months.
The University of Maryland BioPark resident has been a fast grower recently, moving from 100 to 225 employees over the past three years. Paragon says it is the fifth-largest biotechnology company in Maryland.
In addition to the new facility, Paragon also announced new leadership appointments this week: Philip Wills as the company’s chief commercial officer, John Conner as chief manufacturing officer and William Thomas, Jr., as chief scientific officer.
Paragon also hired Randy Henrickson as vice president of manufacturing and Dermot McCaul as vice president of Information Technology.